Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adams Respiratory Therapeutics, Inc.
Adams Respiratory posts 29% increase in sales
June 2nd, 2006
Adams Respiratory Therapeutics, Inc., (ARxT) announced financial results for the fiscal third quarter ended Mar. 31, 2006. Commenting on the results for the quarter, Michael J. Valentino, president and CEO said, "This has been a quarter of excellent financial performance driven by strong market penetration of the Mucinex franchise. Successful execution in the marketplace was also a key contributor. We made solid progress in manufacturing and increased production at a newly qualified Cardinal facility in Winchester, Kentucky. "This allowed us to produce and ship product in excess of our previously stated topline guidance of between $72 and $75 million...
Source: Medicine & Law Weekly (2006-06-02)
|
